UBS downgraded ResMed to Neutral from Buy with a price target of $170, down from $265. The stock is down 28% since FY23 results as the GLP-1 weight loss thesis “has now become firmly rooted in the RMD story,” the analyst tells investors. After reviewing the GLP-1 literature, the firm concludes that Eli Lilly’s (LLY) SURMOUNT-OSA trial is likely to succeed in the first half of 2024, triggering better U.S. access, and lowered its long-term sales growth rates from mid- to low- single digits for ResMed on the potential that sleep apnea patients start taking weight loss drug and create a volume headwind for ResMed’s Sleep business by the 2030s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RMD:
- ResMed Announces Participation in Upcoming Conferences
- Early notable gainers among liquid option names on August 30th
- Early notable gainers among liquid option names on August 15th
- ResMed price target lowered to $273 from $284 at RBC Capital
- Early notable gainers among liquid option names on August 7th